The SLC17A (solute carrier family 17) family comprises a group of membrane transport proteins that play key roles in the transport of a variety of substrates, including organic anions, phosphates, and neurotransmitters. Members of this family are primarily known as phosphate transporters (SLC17A1-4) and vesicular glutamate transporters (VGLUTs, SLC17A5-7). The phosphate transporters are involved in the renal reabsorption of phosphate, a critical process for maintaining phosphate homeostasis, bone mineralization, and overall metabolic function. The VGLUTs are crucial in the central nervous system, where they transport glutamate into synaptic vesicles, facilitating excitatory neurotransmission. The signaling and function of SLC17A transporters are essential in various physiological processes, from bone health to nerve communication, and their dysfunction is implicated in several diseases, including neurological disorders and phosphate metabolism abnormalities.
Targeting SLC17A signaling for disruption or inhibition with small molecules enables a more detailed understanding of the diverse roles these transporters play in physiological and pathological processes. By inhibiting specific SLC17A transporters, researchers can delineate their individual contributions to phosphate homeostasis and neurotransmitter regulation. Such targeted approaches are crucial in elucidating the mechanisms of diseases related to phosphate imbalance or glutamate signaling disorders. Additionally, the use of small molecule inhibitors can shed light on the potential targets within the SLC17A family for conditions like osteoporosis or neurodegenerative diseases.
SEE ALSO...
Items 11 to 20 of 23 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sofosbuvir | 1190307-88-0 | sc-482362 | 25 mg | $146.00 | 1 | |
An ecto-ATPase inhibitor, potentially altering extracellular ATP levels, indirectly affecting SLC17A. | ||||||
FCCP | 370-86-5 | sc-203578 sc-203578A | 10 mg 50 mg | $94.00 $355.00 | 46 | |
A protonophore, disrupts proton gradients, potentially influencing SLC17A function. | ||||||
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | $32.00 | 3 | |
A nonsteroidal anti-inflammatory drug, may indirectly affect ion channels and transporters like SLC17A. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $28.00 $39.00 $100.00 $277.00 | 28 | |
Competitively inhibits various anion transporters, potentially reducing the function of SLC17 family members. | ||||||
Phloridzin dihydrate | 7061-54-3 | sc-215708 sc-215708A | 250 mg 1 g | $49.00 $119.00 | ||
Inhibits sodium-dependent transporters, might reduce competitive uptake of phosphate. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Non-selectively inhibits various membrane proteins, possibly altering SLC17A-related transport. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
Inhibits anion transporters indirectly by affecting prostaglandin synthesis, altering renal transport dynamics. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $41.00 | ||
A loop diuretic that inhibits the NKCC2, can have secondary effects on phosphate transport. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $109.00 $228.00 | 9 | |
Similar to Furosemide, inhibits NKCC2 which could indirectly influence SLC17A activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Affects inositol monophosphatase leading to changes in anion transport, could alter SLC17A function. | ||||||